Champions Oncology Inc Dossier - Source-backed chat

Champions Oncology Inc

CSBRNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.60

Intrinsic Value $6.68median of 2 methodsbased on filings through 31 Jul 2026

Market Price $4.88Price as of 1 Oct 2026

UndervaluedIntrinsic value is 37% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $67.9M

Enterprise Value $63.6M

Shares Outstanding 13.8M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Champions Oncology is undergoing a strategic transition under new CEO Rob Brainin, shifting from a pure-play oncology contract research organization (CRO) to a high-margin, data-driven precision oncology platform. While core study service revenue remains robust (growing 32% YoY in Q3 FY2026), overall profitability has been temporarily pressured by the absence of large, lumpy data licensing deals and elevated outsourced laboratory costs. The company's long-term success hinges on its ability to successfully bring outsourced services in-house to restore gross margins and to commercialize its proprietary multi-omics data platform and Corellia AI subsidiary. Given these transitional headwinds and near-term margin compression, a Hold recommendation is warranted until execution on margin recovery and data monetization becomes clearer.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.0020%

In-sourcing efforts face operational delays, leaving gross margins depressed below 50% due to persistent high outsourced lab costs. Customer biopharma R&D budgets tighten further, slowing backlog conversion and core study growth. The company fails to secure external funding for Corellia AI, forcing it to either absorb high R&D burn or scale back its discovery pipeline, while data licensing deals remain elusive.

Base CaseCentral scenario

$12.0065%

The core CRO business continues to convert its backlog efficiently, maintaining double-digit study service revenue growth. Gross margins gradually recover to the low-to-mid 50% range as radiolabeling and other outsourced services are brought in-house. The data business secures moderate, recurring licensing deals rather than relying on sporadic multi-million dollar transactions, stabilizing quarterly revenue. Corellia AI secures external funding, reducing the R&D cash burn on the parent company.

Bull CaseUpside scenario

$12.0025%

The core CRO business accelerates to high double-digit growth driven by strong demand for radiopharmacology and ex vivo platforms. Gross margins expand rapidly past 55% as in-house radiolabeling capabilities yield significant cost efficiencies. The data business secures multiple high-value, multi-year licensing deals for Lumin and the PPMO database, driving high-margin recurring revenue. Corellia AI successfully completes a major external funding round at a favorable valuation, validating the platform and eliminating R&D cash drag on the parent company.

Scenarios reflect our research view at the research date.

Key Investment Merits

Strong operational momentum in core study services, highlighted by 32% YoY growth in Q3 FY2026.
Differentiated asset in its highly characterized, clinically annotated Patient-Derived Xenograft (PDX) bank of over 1,400 models.
Strategic pivot toward high-margin data assets and AI-driven drug discovery (Corellia AI) which could significantly expand valuation multiples.
Maintains a solid balance sheet with $7.1 million in cash and zero debt as of Q3 FY2026.

Key Investment Risks

Margin compression driven by rising costs of outsourced laboratory services and mice.
High quarterly revenue volatility due to dependence on the timing of large, non-recurring data licensing transactions.
Execution risk associated with transitioning outsourced services in-house.
Potential cash burn acceleration if the Corellia AI subsidiary fails to secure external venture funding.

Thesis Invalidation Triggers

Core study service revenue growth decelerates to single digits.
Gross margins fall below 45% for consecutive quarters.
Failure to secure external funding or strategic partnerships for Corellia AI within the next 12 months.
Significant cash burn that depletes cash reserves below $3 million, raising liquidity concerns.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.